培菲康联合奥沙拉嗪对溃疡型结肠炎患者的疗效及镜下黏膜病变的影响

目的 探讨培菲康联合奥沙拉嗪对溃疡型结肠炎患者的疗效及对镜下黏膜病变的影响.方法 选取2010年1月至2012年12月来我院就诊的66例溃疡型结肠炎患者,随机分为对照组和治疗组,每组33例,以上两组患者均给予1.0 g奥沙拉嗪,3次/d,治疗组在此基础上加服0.42 g培菲康,4次/d,两组患者疗程均为2个月.比较两组的治疗效果,观察治疗前后两组患者镜下粘膜的变化情况.结果 治疗组的总有效率为93.94%,对照组为75.76%,两组比较差异有统计学意义（P〈0.05）.经治疗后,治疗组镜下粘膜改善情况明显优于对照组,两组比较差异有统计学意义（P〈0.05）.结论 培菲康联合奥沙拉嗪对溃疡型结肠炎患者的疗效优于单一用药,可明显改善镜下粘膜病变,提高溃疡性结肠炎的治愈率,值得临床进一步推广使用.

Clinical efficacy of bifico combined with olsalazine in the treatment of ulcerative colitis and the effect on mucosal lesions under endoscope

Objective To observe the clinical efficacy of bifico combined with olsalazine in the treatment of ulcerative colitis and the effect on mucosal lesions under endoscope. Methods 66 patients with ulcerative colitis in our hospital from January 2010 to December 2012 were randomly divided into treatment group （n --33 ） and control group （n = 33 ）. All the two groups were given 1.0 g of olsalazine, three times daily; while the treatment group was added with 0. 42 g of bifico for four times daily, treatment course of both groups was 2 weeks. The therapeutic effect between the two groups was compared, and the changes on endoscopic mucosal before and after the treatment were observed. Results The total effective rates of treatment group and control group were 93.94% and 75.76% ,there was signifi- cont difference between the two groups （ P 〈 0. 05 ）. After treatment, the endoscopic mucosal changes in treatment group were significantly higher than those in control group, there was significant difference between the two groups （P 〈 0. 05 ）. Conclusion Bifico combined with olsalazine has good clinical efficacy on ulcerative colitis, and it can signifi- cantly improve the endoscopic mucosal lesions and the curative rate of ulcerative colitis. It is worthy of further clinical application.